Category: News

Post

Motif Bio Announces Notice of Allowance for Two U.S. Iclaprim Patents with Expiration in 2037

NEW YORK, Aug. 08, 2018 (GLOBE NEWSWIRE) — Motif Bio plc (AIM/NASDAQ: MTFB) (“Motif Bio” or the “Company”), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has received a Notice of Allowance from the United States Patent and Trademark Office for United States Patent Application Nos. 15/586,021 and 15/586,815. ...

Post

Motif Bio Announces Resignation of Robert Bertoldi from Board of Directors

NEW YORK, July 03, 2018 (GLOBE NEWSWIRE) — Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Robert Bertoldi has informed the Company of his decision to resign from the Board of Directors, effective July 16, 2018. Graham Lumsden, Chief Executive Officer of Motif Bio, said: “On...

Post

Entasis Therapeutics Inc. Joins Antimicrobials Working Group

WASHINGTON D.C., July 2, 2018 /PRNewswire/ — The Antimicrobials Working Group (AWG) announced today the addition of Entasis Therapeutics Inc. (Entasis) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. Entasis utilizes a unique pathogen-targeted approach to develop a robust clinical and pre-clinical pipeline of potential first-...

Post

Efficacy of APX001 in Treatment of Candida Endophthalmitis and Hematogenous meningoencephalitis in the Non-neutropenic Rabbit Model

June 11, 2018/by eallison http://amplyx-da.flywheelsites.com/wp-content/uploads/2019/11/logo.svg 0 0 eallison http://amplyx-da.flywheelsites.com/wp-content/uploads/2019/11/logo.svg eallison2018-06-11 13:29:282018-06-11 13:29:28Efficacy of APX001 in Treatment of Candida Endophthalmitis and Hematogenous meningoencephalitis in the Non-neutropenic Rabbit Model Scroll to top READ FULL TEXT